NZ Immuno-Oncology Research Review Issue 20

In this issue:

  - Sintilimab + chemotherapy for locally advanced/metastatic oesophageal SCC
  - Pembrolizumab in completely resected stage IIB or IIC melanoma
  - Nivolumab + chemotherapy in resectable lung cancer
  - Adjuvant durvalumab uptake after chemoradiotherapy for stage III NSCLC
  - Nivolumab + ipilimumab for unresectable malignant pleural mesothelioma
  - Maintenance ICIs ±pemetrexed in advanced nonsquamous NSCLC
  - Nivolumab + ipilimumab vs. sunitinib in advanced RCC
  - Lenvatinib ±ICI for unresectable HCC in the real world
  - Pembrolizumab for advanced HCC previously treated with sorafenib
  - Pembrolizumab in MSI-high advanced endometrial cancer
  -  Pembrolizumab for MSI-high/mismatch repair-deficient metastatic CRC

Please login below to download this issue (PDF)